In8Bio (INAB) Restructuring Costs (2024)
In8Bio's (INAB) quarterly Restructuring Costs came in at $1.1 million in Q3 2024.
Powered by 
Analysis
In8Bio (INAB) Restructuring Costs (2024) Analysis & Trends
In8Bio has disclosed Restructuring Costs across 1 years of filings, most recently posting $1.1 million for Q3 2024.
- In Q3 2024, Restructuring Costs changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (changed N/A YoY), while the FY2024 annual figure was $1.1 million, changed N/A from the prior year.
- Restructuring Costs came in at $1.1 million for Q3 2024 at In8Bio.
- In the past five years, Restructuring Costs ranged from a high of $1.1 million in Q3 2024 to a low of $1.1 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.38 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.06 Bn | 5.06 Bn | - |
| 3 | Iovance Biotherapeutics | 3.73 Bn | 3.43 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.61 Bn | 2.65 Bn | 251.50 Mn |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - |
| 7 | Precigen | 2.37 Bn | 2.37 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.24 Bn | 1.44 Bn | 251.87 Mn |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn |
| 10 | In8Bio | 21.61 Mn | 21.61 Mn | - |